- A study reports: 'The relative risk of developing diabetes was 2.3 (95% CI: 1.4, 3.8) for obese compared to normal-weight individuals.' Which interpretation is most precise?
Answer: Obese individuals have 2.3 times the risk of developing diabetes compared to normal-weight individuals.
When you encounter relative risk (RR) questions, focus on precise mathematical interpretation rather than colloquial language that can introduce ambiguity.
Relative risk represents a ratio: the risk in the exposed group divided by the risk in the unexposed group. An RR of 2.3 means the exposed group (obese individuals) has exactly 2.3 times the risk of the unexposed group (normal-weight individuals). This is a multiplicative relationship, not an additive one.
Answer C correctly states this mathematical relationship: obese individuals have 2.3 times the risk compared to normal-weight individuals. This phrasing captures the precise ratio without additional interpretation.
Answer A uses "more likely," which can be ambiguous—does this mean 2.3 times as likely or 2.3 times more likely? In statistics, we avoid this ambiguous phrasing. Answer B incorrectly converts to percentage increase. A 130% increase would mean the risk is 2.3 times higher (230% of baseline), but this adds unnecessary conversion and potential confusion. The original RR value is more precise. Answer D suggests causation ("when individuals become obese") and implies the RR measures probability change over time, but relative risk compares risks between groups at a point in time, not probability changes within individuals.
Remember: When interpreting relative risk, stick to the mathematical ratio language ("X times the risk") rather than converting to percentages or using potentially ambiguous phrases like "more likely." This maintains statistical precision and avoids common misinterpretations.
- A pharmaceutical company conducted a non-inferiority trial comparing a generic drug to the brand-name version. The primary endpoint showed a difference in efficacy of -2.1% (95% CI: -5.8% to 1.6%) favoring the brand drug, with a pre-specified non-inferiority margin of -10%. The p-value for superiority was 0.24. Which conclusion is most appropriately stated?
Answer: Non-inferiority was demonstrated as the lower confidence bound (-5.8%) exceeded the pre-specified margin (-10%), indicating the generic drug performs acceptably compared to the brand formulation.
Choice D correctly explains the non-inferiority criterion (lower CI bound must exceed the margin), uses appropriate language, and draws the correct conclusion. Choice A correctly states non-inferiority but unnecessarily mentions the irrelevant superiority test. Choice B is correct but uses awkward phrasing and focuses on the wrong comparison. Choice C incorrectly describes the p-value as testing difference rather than superiority and uses confusing language about 'significantly different.'
- A clinical trial reports: 'The mean reduction in systolic blood pressure was 12.3 mmHg (SD = 4.8) in the treatment group compared to 3.1 mmHg (SD = 4.2) in the placebo group (p < 0.001).' What additional information is most critical for complete reporting?
Answer: The confidence interval for the difference between group means and the sample sizes.
When evaluating statistical reporting in clinical trials, you should always ask: "Do I have enough information to understand the magnitude of the effect and how confident I can be in these results?" The reported means, standard deviations, and p-value tell you there's a statistically significant difference, but they don't give you the complete picture needed for clinical interpretation.
Answer B is correct because confidence intervals and sample sizes are essential for complete reporting. The confidence interval for the difference between means (12.3 - 3.1 = 9.2 mmHg difference) would show you the range of plausible values for the true treatment effect, giving you crucial information about both the precision of the estimate and its clinical significance. Sample sizes are equally critical because they affect the reliability of your results and help readers assess whether the study was adequately powered.
Answer A is incorrect because correlation between baseline values and response, while potentially interesting, isn't required for basic statistical reporting and doesn't address the completeness of the main comparison. Answer C focuses on median and IQR, which would be more relevant if you suspected non-normal distributions, but the study already reports means and standard deviations appropriately. Answer D mentions effect size and power analysis, which are valuable but secondary to the fundamental need for confidence intervals and sample sizes that directly relate to the reported comparison.
Remember: whenever you see means compared between groups, immediately look for confidence intervals around the difference and sample sizes. These transform a simple "statistically significant" finding into clinically interpretable evidence.
- A diagnostic accuracy study evaluated a new biomarker for detecting early-stage cancer. The sensitivity was 78% (95% CI: 71-84%) and specificity was 85% (95% CI: 80-89%) in a sample of 450 patients. The area under the ROC curve was 0.89 (95% CI: 0.85-0.92). How should these diagnostic performance measures be reported?
Answer: The biomarker showed 78% sensitivity (95% CI: 71-84%) and 85% specificity (95% CI: 80-89%) for cancer detection, with good overall diagnostic accuracy (AUC=0.89, 95% CI: 0.85-0.92).
Choice B uses precise statistical terminology (sensitivity/specificity), provides complete confidence intervals for all measures, and appropriately describes AUC=0.89 as 'good' diagnostic accuracy. Choice A uses less precise language ('correctly identified') and overstates AUC=0.89 as 'excellent.' Choice C omits the AUC confidence interval and uses imprecise terminology. Choice D uses correct but less standard terminology (true positive/negative rates) and overstates the discriminatory power as 'strong.'
- A clinical trial comparing two pain medications found the following results: Drug A reduced pain scores by a mean of 2.8 points (95% CI: 2.1-3.5) and Drug B by 2.3 points (95% CI: 1.7-2.9) on a 10-point scale. The between-group comparison showed a difference of 0.5 points (95% CI: -0.4 to 1.4, p=0.28). The minimal clinically important difference was pre-defined as 1.0 point. How should these results be interpreted and reported?
Answer: Both medications produced statistically significant pain reduction from baseline, with Drug A reducing scores by 2.8 points (95% CI: 2.1-3.5) and Drug B by 2.3 points (95% CI: 1.7-2.9). The between-group difference of 0.5 points (95% CI: -0.4 to 1.4, p=0.28) was neither statistically significant nor clinically meaningful (MCID=1.0 point).
When interpreting clinical trial results, you need to distinguish between statistical significance, clinical significance, and the completeness of reporting. This question tests your ability to identify proper scientific communication that addresses all three elements.
Answer A correctly interprets and reports all key findings. It acknowledges that both drugs produced statistically significant reductions from baseline (since neither confidence interval includes zero), reports the between-group comparison with its non-significant p-value (0.28), and explicitly states that the 0.5-point difference is neither statistically significant nor clinically meaningful since it falls below the pre-defined minimal clinically important difference (MCID) of 1.0 point.
Answer B is incomplete because it fails to explicitly state whether the individual drug effects were statistically significant from baseline, which is crucial information for readers. Answer C makes the same omission and uses vague language like "numerically greater" without addressing the clinical significance threshold. Answer D incorrectly concludes "equivalent efficacy" - this is a common error since non-significant results don't prove equivalence. The study wasn't powered as an equivalence trial, and the confidence interval (-0.4 to 1.4) actually includes the MCID of 1.0, meaning a clinically meaningful difference cannot be ruled out.
Study tip: In biostatistics, always report three elements for clinical trials: individual treatment effects with confidence intervals, between-group comparisons with p-values, and clinical significance using pre-defined thresholds. Never confuse "no significant difference" with "equivalence" - they're fundamentally different statistical concepts.
- A researcher writes: 'The treatment was effective (p = 0.04) with a mean improvement of 2.1 points on the depression scale.' What is the primary issue with this statistical reporting?
Answer: Statistical significance does not necessarily indicate clinical effectiveness without context about meaningful change.
When you encounter statistical reporting in research, you need to distinguish between statistical significance and clinical significance—two fundamentally different concepts that are often confused.
The correct answer is B because statistical significance (p = 0.04) only tells you that the observed difference is unlikely due to chance. However, it says nothing about whether that difference is meaningful in real-world clinical practice. A 2.1-point improvement might be statistically significant but clinically trivial if, for example, the depression scale ranges from 0-100 and typical meaningful changes require 10+ points. Without knowing what constitutes a clinically meaningful difference on this particular scale, you cannot conclude the treatment is "effective."
Answer A is wrong because p = 0.04 is definitively below the conventional 0.05 threshold—there's no ambiguity about statistical significance here. Answer C misses the main issue; while scale direction matters for interpretation, the primary problem is the leap from statistical to clinical significance. Answer D identifies important missing information, but sample size and confidence intervals wouldn't resolve the fundamental confusion between statistical and clinical significance.
Remember this key principle: statistical significance answers "Is this difference real?" while clinical significance answers "Does this difference matter to patients?" A p-value can never tell you about clinical effectiveness—you need additional context about what size of change is meaningful in practice. Always be skeptical when researchers jump from p-values to effectiveness claims without discussing clinical significance thresholds.
- A survival analysis of 5-year mortality in heart failure patients (n=450) found that patients with ejection fraction <40% had a median survival of 3.2 years compared to 4.8 years for those with EF≥40%. The hazard ratio was 1.65 (95% CI: 1.28-2.13, p<0.001). How should this survival difference be appropriately communicated?
Answer: Reduced ejection fraction (<40%) was associated with increased mortality (HR=1.65, 95% CI: 1.28-2.13, p<0.001) with median survival times of 3.2 versus 4.8 years for preserved EF patients.
Choice B uses appropriate language for observational data ('associated with'), correctly interprets the hazard ratio, provides complete survival information, and uses precise terminology. Choice A inappropriately implies causation and incorrectly states '65% higher risk' (should be 65% higher hazard rate). Choice C correctly reports statistics but doesn't clearly identify which group had which survival time. Choice D uses awkward phrasing ('conferred,' 'death hazard') and implies causation inappropriately.
- A regression analysis yields: 'For each additional year of age, blood pressure increases by 0.8 mmHg (95% CI: 0.3, 1.3; p = 0.003).' How should the confidence interval be interpreted?
Answer: We are 95% confident that the true relationship between age and blood pressure is between 0.3 and 1.3 mmHg per year.
When you encounter confidence intervals for regression coefficients, you're dealing with statistical inference about the true population relationship between variables, not predictions about individual cases or data distribution.
The confidence interval (0.3, 1.3) represents our uncertainty about the true slope coefficient in the population. Since we calculated this from a sample, our estimate of 0.8 mmHg per year has sampling variability. The 95% confidence interval tells us the plausible range for the true population parameter. Answer C correctly captures this - we're 95% confident the true relationship (slope coefficient) between age and blood pressure lies between 0.3 and 1.3 mmHg per year.
Answer A is wrong because confidence intervals don't predict individual patient outcomes - they estimate population parameters. Individual predictions would require prediction intervals, which account for both parameter uncertainty and individual variability around the regression line.
Answer B uses problematic language by saying "probability that the true slope lies between..." The true slope either is or isn't in this range - we can't assign probability to a fixed parameter. The confidence level refers to our method's long-run performance, not the probability for this specific interval.
Answer D confuses confidence intervals with the distribution of residuals around the regression line. This describes how data points scatter around the fitted line, which is unrelated to our uncertainty about the slope coefficient.
Study tip: Remember that confidence intervals for regression coefficients always estimate uncertainty about the true population relationship, never individual predictions or data scatter. Focus on the parameter being estimated when interpreting any confidence interval.
- A case-control study investigating risk factors for lung cancer included 380 cases and 760 controls. Smoking history showed an odds ratio of 4.2 (95% CI: 2.8-6.3, p<0.001), while family history of cancer had an OR of 1.8 (95% CI: 0.9-3.6, p=0.09). How should these findings be reported in the results section?
Answer: Smoking was strongly associated with lung cancer (OR=4.2, 95% CI: 2.8-6.3, p<0.001). Family cancer history was associated with increased odds (OR=1.8, 95% CI: 0.9-3.6) but this did not reach statistical significance (p=0.09).
Choice C appropriately describes associations in case-control studies, provides complete statistical information, and correctly interprets non-significant findings without dismissing them. Choice A inappropriately uses 'trend' language without justification. Choice B dismisses the non-significant finding inappropriately. Choice D uses acceptable language but is less precise in describing the association and uses awkward phrasing for the non-significant result.
- A researcher reports: 'The odds ratio for smoking and lung cancer was 12.4 (p < 0.001), confirming that smoking causes lung cancer.' What is the primary statistical reporting error?
Answer: Odds ratios cannot establish causation; they only quantify the strength of association between variables.
When you encounter questions about statistical associations and causation, remember that statistical measures can only quantify relationships between variables—they cannot prove that one variable causes another, no matter how strong the association.
The researcher's primary error is claiming that the odds ratio establishes causation. An odds ratio of 12.4 means that people who smoke have 12.4 times the odds of developing lung cancer compared to non-smokers. This is a strong association, but association is not causation. Even with a highly significant p-value, this statistical measure alone cannot prove that smoking causes lung cancer. Establishing causation requires additional evidence including temporal relationships, dose-response patterns, biological plausibility, and consideration of confounding variables.
Looking at the other options: Choice A is a valid concern since confidence intervals provide important information about precision and statistical significance, but it's not the primary error here. Choice C misunderstands p-value reporting—using "p < 0.001" is perfectly acceptable and often preferred when the exact value is extremely small. Choice D incorrectly suggests that large odds ratios are inherently problematic. While unusually large effect sizes warrant scrutiny, an odds ratio of 12.4 is not implausible for well-established risk factors like smoking and lung cancer.
Study tip: Remember the fundamental rule: correlation ≠ causation. No matter how strong an association appears statistically (high odds ratios, low p-values), observational studies can only demonstrate association. Watch for questions that try to trick you into accepting causal language based solely on statistical significance.
- A study comparing medication effectiveness reports: 'Response rates were 45% (18/40) in Group A and 65% (26/40) in Group B, with a significant difference (χ2=3.2,p=0.04).' What should be questioned about this reporting?
Answer: Confidence intervals for the difference in proportions and effect size measures should be included.
When evaluating statistical reporting in biomedical research, complete interpretation requires both statistical significance testing and practical effect assessment. While this study correctly reports the chi-square test results, it's missing crucial information for proper clinical interpretation.
Answer D is correct because comprehensive statistical reporting should include confidence intervals and effect size measures. The confidence interval for the 20% difference in proportions would show the range of plausible true differences, helping readers assess both statistical precision and clinical relevance. Effect size measures (like odds ratio or relative risk) provide standardized ways to interpret the magnitude of treatment effects that complement p-values.
Option A is incorrect—the chi-square value of 3.2 is actually appropriate for this comparison. With these sample sizes and proportions, this statistic correctly reflects the observed difference. Option B is wrong because chi-square is perfectly acceptable here; Fisher's exact test is typically preferred only when expected cell counts fall below 5, which doesn't occur with these sample sizes (both groups have 40 participants). Option C, while raising a valid clinical consideration, isn't the primary statistical reporting issue—the 20% absolute difference could indeed be clinically meaningful depending on the condition and intervention context.
Remember that p-values only tell you if a difference is statistically significant, not how large or clinically important that difference is. Always look for confidence intervals and effect sizes in research reports—their absence is a red flag for incomplete statistical communication, even when significance testing is performed correctly.
- A study reports: 'Treatment A showed superior outcomes with an effect size of d = 0.8.' A reviewer questions this interpretation. What is the most likely concern?
Answer: The term 'superior outcomes' implies clinical significance that cannot be determined from effect size alone.
When you encounter questions about effect sizes and clinical interpretations, focus on the crucial distinction between statistical significance and clinical significance. These are fundamentally different concepts that researchers and clinicians must carefully separate.
The reviewer's most likely concern is that claiming "superior outcomes" implies clinical significance, which cannot be determined from Cohen's d alone. While d = 0.8 indicates a large statistical effect, clinical significance depends on whether this translates to meaningful improvements in patient outcomes, quality of life, or other clinically relevant measures. A statistically large effect might represent a small, clinically irrelevant difference in the actual measured outcome.
Let's examine why the other options miss the mark: Option A incorrectly suggests the primary issue is reporting format—while confidence intervals and sample sizes improve interpretation, they don't address the clinical significance problem. Option B is factually wrong since d = 0.8 represents a large effect size by Cohen's conventions (small = 0.2, medium = 0.5, large = 0.8). Option D focuses on a statistical assumption that, while potentially important, isn't the most likely concern a reviewer would raise about claims of "superior outcomes."
Remember this key principle: effect size tells you the magnitude of difference between groups, but only clinical expertise and context can determine if that difference matters to patients. When you see researchers making clinical claims based solely on statistical measures, always question whether they've bridged the gap between statistical and clinical significance.
- A researcher reports a 95% confidence interval for mean weight loss as (1.2, 4.8) kg. A colleague suggests this should be written as: 'Participants lost 3.0 ± 1.8 kg (95% CI).' What is wrong with the colleague's suggestion?
Answer: The notation 3.0 ± 1.8 represents margin of error, not the confidence interval bounds for this estimate.
When interpreting confidence intervals, you need to understand what different notation formats communicate about statistical uncertainty and what parameter is being estimated.
The colleague's suggestion of "3.0 ± 1.8 kg (95% CI)" is mathematically correct—it does yield the interval (1.2, 4.8). However, this plus-minus format creates confusion about what type of uncertainty is being reported. In statistical writing, the ± notation is typically reserved for standard errors or standard deviations, not confidence intervals. When readers see ±1.8, they naturally interpret this as one standard error, suggesting they could multiply by 1.96 to get the 95% confidence interval. This misrepresents the actual statistical calculation that produced the interval.
Looking at the wrong answers: Choice A incorrectly suggests that confidence intervals should never use plus-minus notation—while not preferred, it's not inherently wrong. Choice B misunderstands the issue by focusing on distribution symmetry, but the calculation itself is mathematically sound regardless of the underlying distribution shape. Choice D misses the mark by suggesting confusion about sample versus population means, but both formats are clearly reporting sample statistics as estimates of population parameters.
The core problem is that the plus-minus notation misleadingly suggests standard error reporting rather than a confidence interval, potentially confusing readers about the type of uncertainty measure being presented.
Study tip: Always report confidence intervals in interval notation (a, b) to avoid confusion with standard errors. Reserve ± notation for standard deviations and standard errors only.
- A t-test comparing two groups yields: t(48) = 2.34, p = 0.023. The researcher writes: 'Group A performed significantly better than Group B.' What reporting element is most critically missing?
Answer: The actual group means and standard deviations are needed to interpret the magnitude of difference.
When interpreting statistical test results, you must be able to determine what the numbers actually tell you about the real-world difference between groups. The researcher's conclusion about "Group A performing significantly better" cannot be validated from the given information.
The t-statistic and p-value tell us there's a statistically significant difference, but they don't reveal which group had higher values. A positive t-statistic (2.34) could mean Group A > Group B or Group B > Group A, depending on how the researcher coded the groups in the analysis. Without seeing the actual means, you cannot determine the direction of the difference, making the researcher's directional claim unjustified.
Looking at the wrong answers: (A) is incorrect because the direction actually cannot be determined from a t-statistic alone - this supports why (B) is correct rather than contradicting it. (C) identifies confidence intervals as missing, which would be valuable but isn't the most critical omission when you can't even verify the basic claim about which group performed better. (D) points to missing effect size, which is important for interpreting practical significance, but again, you first need to know the direction of the difference before worrying about its magnitude.
For biostatistics questions involving test interpretation, always ask yourself: "Can I verify the researcher's specific claims from the given statistics?" When you see directional conclusions ("A is better than B"), immediately check whether the reported statistics actually support that direction. Means and standard deviations are your foundation for interpreting any between-group comparison.
- A cross-sectional study examined the correlation between physical activity levels and depression scores in 340 adults. The Pearson correlation coefficient was r = -0.34 (95% CI: -0.44 to -0.23, p<0.001), with physical activity explaining 12% of the variance in depression scores. Which interpretation is most scientifically accurate?
Answer: There was a statistically significant moderate negative association between physical activity and depression (r=-0.34, 95% CI: -0.44 to -0.23, p<0.001), with shared variance of 12% between these variables.
Choice D correctly describes the relationship as an 'association,' appropriately characterizes r=-0.34 as moderate, provides complete statistical reporting, and accurately describes r²=0.12 as 'shared variance' without implying causation. Choice A inappropriately implies causation ('reduces depressive symptoms'). Choice B uses imprecise language ('associated with 12% of variance'). Choice C implies causation with 'explained by' and uses awkward statistical reporting order.
- A chi-square test yields χ2=8.94,df=3,p=0.030. The researcher writes: 'The variables are significantly associated.' What additional reporting would be most valuable?
Answer: A measure of effect size such as Cramér's V and a description of the pattern of association.
When you encounter a significant chi-square test result, you're only halfway through proper statistical reporting. A significant p-value tells you that an association exists, but it doesn't tell you how strong that association is or what pattern it follows.
Answer B is correct because it addresses both critical gaps in the researcher's statement. Cramér's V quantifies the strength of association on a 0-1 scale, giving readers meaningful context about whether this significant result represents a weak, moderate, or strong relationship. With χ2=8.94 and df=3, you can calculate Cramér's V to determine practical significance beyond statistical significance. Equally important is describing the pattern—which categories are over- or under-represented relative to what you'd expect if variables were independent.
Answer A provides transparency but doesn't enhance interpretation of the significant finding. Raw data alone doesn't help readers understand the strength or nature of the association. Answer C suggests post-hoc cell comparisons, but chi-square tests don't require multiple comparison corrections like ANOVA does—the overall test already tells you about association patterns. Answer D addresses methodological rigor, which is important for validity but doesn't improve interpretation of an already-conducted analysis.
Remember this hierarchy for chi-square reporting: statistical significance first (already established), then effect size and pattern description (missing here), then methodological details if space permits. On biostatistics exams, questions about "most valuable additional reporting" typically prioritize interpretive information that helps readers understand both the magnitude and nature of significant findings. - A meta-analysis of 15 studies examined the relationship between vitamin D supplementation and fracture risk. The pooled odds ratio was 0.84 (95% CI: 0.72-0.98, p=0.03) with moderate heterogeneity (I² = 45%). Which statement best describes the appropriate interpretation and limitations?
Answer: Meta-analysis showed vitamin D supplementation was associated with reduced fracture odds (pooled OR=0.84, 95% CI: 0.72-0.98), but moderate heterogeneity (I²=45%) suggests caution in interpretation.
Choice B appropriately uses observational language ('associated with'), correctly interprets moderate heterogeneity as warranting caution, and avoids overstating conclusions. Choice A inappropriately uses causal language ('prevents') and dismisses the heterogeneity concern. Choice C uses causal language ('reduces...by') and incorrectly characterizes I²=45% as 'acceptable consistency.' Choice D uses causal language ('decreases') and understates the importance of heterogeneity for interpretation.
- A study found a correlation coefficient of r = 0.72 between hours of exercise per week and cardiovascular fitness scores. Which statement best describes how this finding should be reported?
Answer: There is a strong positive association between weekly exercise hours and fitness scores (r = 0.72).
When you encounter correlation coefficients in biostatistics, remember that they measure the strength and direction of linear relationships between variables, not causation or specific predictive values.
The correlation coefficient r = 0.72 indicates a strong positive association between exercise hours and fitness scores. Since correlations range from -1 to +1, a value of 0.72 represents a strong positive relationship—as one variable increases, the other tends to increase as well. Answer B correctly describes this as "a strong positive association" and properly includes the correlation value for transparency.
Let's examine why the other options are incorrect. Answer A claims "exercise causes a 72% improvement," which confuses correlation with causation—correlation studies cannot establish causal relationships, and the 0.72 value doesn't represent a percentage change. Answer C states that "exercise hours explain 72% of the variation," but this misinterprets the correlation coefficient. To find explained variation, you'd calculate r², which would be 0.72² = 0.52 or 52%. Answer D suggests "fitness increases by 0.72 units for each additional exercise hour," which confuses correlation coefficients with regression slopes—these are entirely different statistical measures.
Study tip: Remember that correlation coefficients only describe association strength and direction. For causation, you need experimental designs. For percentage of explained variance, square the correlation coefficient (r²). For predicting specific unit changes, you need regression analysis, not correlation.
- A study reports: 'No significant difference was found between groups (p = 0.12).' Which follow-up statement would be most appropriate?
Answer: The study failed to detect a difference, but this does not prove that no difference exists.
When you encounter a non-significant p-value in biostatistics, you're dealing with one of the most commonly misunderstood concepts in statistical inference. The key principle here is that "absence of evidence is not evidence of absence."
A p-value of 0.12 means that if there truly were no difference between groups, you would observe results this extreme or more extreme about 12% of the time by random chance alone. Since this exceeds the conventional significance threshold of 0.05, we fail to reject the null hypothesis. However, this doesn't prove the null hypothesis is true.
Answer B correctly captures this nuance: failing to detect a difference doesn't prove no difference exists. The study may have been underpowered, the effect size may be small, or there may be other methodological limitations preventing detection of a real difference.
Answer A is wrong because statistical tests never "prove" anything about entire populations with certainty. Answer C misinterprets the p-value—it's not the probability that the null hypothesis is correct. The p-value tells us about the probability of observing our data given the null hypothesis, not the probability of the null hypothesis being true. Answer D is incorrect because we cannot definitively attribute observed differences to random error when we fail to find significance; there could still be a real effect we simply didn't detect.
Remember: non-significant results indicate insufficient evidence for a difference, not proof of no difference. Always consider study power and effect size when interpreting negative results.
- A confidence interval for the difference in mean cholesterol levels between treatment and control groups is reported as (2.4, 18.7) mg/dL. How should this result be interpreted in a research report?
Answer: We are 95% confident that the true difference in mean cholesterol levels between groups is between 2.4 and 18.7 mg/dL.
When you encounter confidence interval interpretation questions, remember that these intervals make statements about population parameters, not individual samples or future observations.
The confidence interval (2.4, 18.7) mg/dL represents our best estimate of where the true population difference in mean cholesterol levels lies. Since both bounds are positive, we can infer that the treatment group likely has higher cholesterol levels than the control group, with the true difference falling somewhere in this range.
Answer B correctly interprets this as a statement about our confidence in where the true population parameter (the difference in means) lies. The 95% confidence level means that if we repeated this study many times with the same methodology, 95% of the resulting confidence intervals would contain the true population difference.
Answer A incorrectly uses the phrase "95% certainty," which implies probability about the parameter itself. The parameter is fixed; our interval either contains it or doesn't. The 95% refers to our confidence in the method, not certainty about this specific interval.
Answer C misinterprets the interval as predicting future sample results. Confidence intervals describe population parameters, not future sample outcomes, which would require prediction intervals instead.
Answer D confuses the confidence interval with an expected range for observed differences. The interval estimates the true population difference, not the range where we expect future observed differences to fall.
Study tip: Remember that confidence intervals always make statements about population parameters, and the confidence level refers to the long-run performance of the method, not the probability that this specific interval contains the parameter.
